Joel Isaacson & Co’s Ironwood Pharmaceuticals IRWD Stock Holding History

Joel Isaacson & Co’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,179	Closed	-$105K	–	343
2016 Q4	$105K	Hold	8,179	–	–	0.02%	218
2016 Q3	$109K	Buy	+8,179	New	+$95.6K	0.02%	222
2015 Q4	–	Sell	-6,567	Closed	-$57K	–	769
2015 Q3	$57K	Hold	6,567	–	–	0.02%	320
2015 Q2	$66K	Hold	6,567	–	–	0.02%	323
2015 Q1	$88K	Hold	6,567	–	–	0.02%	274
2014 Q4	$84K	Hold	6,567	–	–	0.02%	252
2014 Q3	$71K	Buy	6,567 +1,194	+22%	+$13.7K	0.02%	251
2014 Q2	$69K	Hold	5,373	–	–	0.02%	258
2014 Q1	$55K	Hold	5,373	–	–	0.02%	279
2013 Q4	$52K	Sell	5,373 -3,582	-40%	-$32.2K	0.02%	261
2013 Q3	$89K	Hold	8,955	–	–	0.04%	189
2013 Q2	$74K	Buy	+8,955	New	+$109K	0.03%	182

Other funds holding IRWD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Joel Isaacson & Co's IRWD Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2017, closing a stake of 8,179 shares — an estimated $105K sold.

Joel Isaacson & Co first reported a position in IRWD in Q2 2013 and held it in 12 quarters. The position peaked at $109K in Q3 2016. 162 funds tracked by Wall St. Rank hold IRWD as of Q1 2017.

Joel Isaacson & Co reported no remaining Ironwood Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Joel Isaacson & Co sold 8,179 Ironwood Pharmaceuticals shares in Q1 2017, an estimated $105K.
Joel Isaacson & Co first reported a position in Ironwood Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Joel Isaacson & Co's Ironwood Pharmaceuticals position peaked at $109K in Q3 2016.
162 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.